New Data from Peking University Cancer Hospital Illuminate Research in Apoptosis (Boosting synergism of chemo- and immuno-therapies via switching paclitaxel-induced apoptosis to mevalonate metabolism-triggered ferroptosis by bisphosphonate...).

A new report from Peking University Cancer Hospital in Beijing, China, discusses research on apoptosis, a form of cell death. The study focuses on the challenges faced by conventional chemotherapy in light of advancements in monoclonal antibodies and targeted drugs. The researchers propose a new approach using bisphosphonate coordination lipid nanogranules (BC-LNPs) loaded with paclitaxel (PTX) to enhance the effectiveness of cytotoxic drugs. By inhibiting mevalonate metabolism, the BC-LNPs@PTX trigger a form of cell death called ferroptosis, which remodels the tumor immune microenvironment and synergizes with immunotherapy. This research provides new insights into the development of cytotoxic drugs and highlights the potential of metabolism regulation in cancer therapy. [Extracted from the article]